{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:00:30Z","timestamp":1790470830179,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T00:00:00Z","timestamp":1782000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF24OC0088207"],"award-info":[{"award-number":["NNF24OC0088207"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008394","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["9064-00062B"],"award-info":[{"award-number":["9064-00062B"]}],"id":[{"id":"10.13039\/100008394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001732","name":"Danish National Research Foundation","doi-asserted-by":"publisher","award":["DNRF141"],"award-info":[{"award-number":["DNRF141"]}],"id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","award":["R368\\u20132021-726"],"award-info":[{"award-number":["R368\\u20132021-726"]}],"id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008733","name":"Erik H\u00f8rslev and Birgit H\u00f8rslev Fund","doi-asserted-by":"publisher","award":["41,301,763.1"],"award-info":[{"award-number":["41,301,763.1"]}],"id":[{"id":"10.13039\/100008733","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001825","name":"Danish Agency for Higher Education and Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijbiomac.2026.153145","type":"journal-article","created":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T22:06:39Z","timestamp":1782079599000},"page":"153145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and preclinical evaluation of an asialoglycoprotein receptor 1-targeted antibody-drug conjugate in hepatic inflammation"],"prefix":"10.1016","volume":"377","author":[{"given":"Vineesh","family":"Indira Chandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stig Hill","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Maria","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Novera","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Marie","family":"Pr\u00e6stholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolaj","family":"Toft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseelan","family":"Palarasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Kl\u00f8jgaard","family":"Skytthe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren Kragh","family":"Moestrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Gr\u00f8ntved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changzhu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Lykke-M\u00f8ller","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henricus Antonius Maria","family":"Mutsaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas Heilskov","family":"Graversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41392-024-02072-z","article-title":"Liver diseases: epidemiology, causes, trends and predictions","volume":"10","author":"Gan","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.153145_bb0010","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal Arun","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"10019","key":"10.1016\/j.ijbiomac.2026.153145_bb0020","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153145_bb0025","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153145_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9972","key":"10.1016\/j.ijbiomac.2026.153145_bb0035","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.153145_bb0045","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153145_bb0050","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153145_bb0055","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"Autoimmune hepatitis","volume":"63","author":"EASL Clinical Practice Guidelines","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0060","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications","volume":"203","author":"D\u2019Souza","year":"2015","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0070","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/08982104.2012.662653","article-title":"Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma","volume":"22","author":"Varshosaz","year":"2012","journal-title":"J. Liposome Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/02841860310023525","article-title":"A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer","volume":"43","author":"Mok","year":"2004","journal-title":"Acta Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0080","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jconrel.2005.12.023","article-title":"Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting","volume":"111","author":"Terada","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0085","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0076-6879(10)79013-3","article-title":"The Ashwell-Morell receptor","volume":"479","author":"Grewal","year":"2010","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0090","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0076-6879(74)34090-6","article-title":"A membrane receptor protein for asialoglycoproteins","volume":"34","author":"Pricer","year":"1974","journal-title":"Methods Enzymol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0095","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1083\/jcb.90.3.687","article-title":"Galactose-specific recognition system of mammalian liver: receptor distribution on the hepatocyte cell surface","volume":"90","author":"Wall","year":"1981","journal-title":"J. Cell Biol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0100","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(83)90518-4","article-title":"Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis","volume":"32","author":"Geuze","year":"1983","journal-title":"Cell"},{"issue":"43","key":"10.1016\/j.ijbiomac.2026.153145_bb0105","doi-asserted-by":"crossref","first-page":"10009","DOI":"10.1021\/bi00495a001","article-title":"The asialoglycoprotein receptor: a model for endocytic transport receptors","volume":"29","author":"Spiess","year":"1990","journal-title":"Biochemistry"},{"issue":"1\u20132","key":"10.1016\/j.ijbiomac.2026.153145_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0014-5793(98)00947-8","article-title":"Ligand-induced endocytosis of the asialoglycoprotein receptor: evidence for heterogeneity in subunit oligomerization","volume":"434","author":"Bider","year":"1998","journal-title":"FEBS Lett."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.153145_bb0115","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1111\/j.1742-4658.2012.08643.x","article-title":"NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes","volume":"279","author":"Onizuka","year":"2012","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0120","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1208\/s12248-013-9474-6","article-title":"Comparative <i>in silico\u2013in vivo<\/i> evaluation of ASGP-R ligands for hepatic targeting of curcumin Gantrez nanoparticles","volume":"15","author":"D\u2019Souza","year":"2013","journal-title":"AAPS J."},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0125","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jconrel.2014.03.028","article-title":"Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates","volume":"183","author":"Barrett","year":"2014","journal-title":"Journal of controlled release\u202f: official journal of the Controlled Release Society"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153145_bb0130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153145_bb0135","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1021\/cb501028c","article-title":"SiRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes","volume":"10","author":"Matsuda","year":"2015","journal-title":"ACS Chem. Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153145_bb0140","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/cbic.201500023","article-title":"Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo","volume":"16","author":"Rajeev","year":"2015","journal-title":"Chembiochem"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0145","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acs.biomac.5b01555","article-title":"N-Acetylgalactosamine block-co-Polycations form stable Polyplexes with plasmids and promote liver-targeted delivery","volume":"17","author":"Dhande","year":"2016","journal-title":"Biomacromolecules"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0150","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bmc.2015.11.036","article-title":"Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides","volume":"24","author":"Yamamoto","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"28","key":"10.1016\/j.ijbiomac.2026.153145_bb0155","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1002\/adma.201601064","article-title":"Superfluorinated PEI derivative coupled with (99m) Tc for ASGPR targeted (19) F MRI\/SPECT\/PA tri-modality imaging","volume":"28","author":"Guo","year":"2016","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ymthe.2017.08.019","article-title":"Evaluation of GalNAc-siRNA conjugate activity in pre-clinical animal models with reduced Asialoglycoprotein receptor expression","volume":"26","author":"Willoughby","year":"2018","journal-title":"Mol. Ther."},{"issue":"49","key":"10.1016\/j.ijbiomac.2026.153145_bb0165","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J. Am. Chem. Soc."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153145_bb0170","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ymthe.2016.10.019","article-title":"Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate","volume":"25","author":"Zimmermann","year":"2017","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0180","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"issue":"19","key":"10.1016\/j.ijbiomac.2026.153145_bb0185","doi-asserted-by":"crossref","first-page":"10969","DOI":"10.1093\/nar\/gkx818","article-title":"Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates","volume":"45","author":"Nair","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody\u2013drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153145_bb0195","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153145_bb0200","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/1541-7786.MCR-19-0856","article-title":"Hypoxia attenuates Trastuzumab uptake and Trastuzumab-Emtansine (T-DM1) cytotoxicity through redistribution of phosphorylated Caveolin-1","volume":"18","author":"Indira Chandran","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153145_bb0205","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/mt.2012.103","article-title":"Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone","volume":"20","author":"Graversen","year":"2012","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153145_bb0210","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2011.10.021","article-title":"Anti-cancer activity of an acid-labile N-alkylisatin conjugate targeting the transferrin receptor","volume":"316","author":"Indira Chandran","year":"2012","journal-title":"Cancer Lett."},{"issue":"20","key":"10.1016\/j.ijbiomac.2026.153145_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/app11209437","article-title":"Quantification for antibody-conjugated drug in Trastuzumab Emtansine and application to in vitro linker stability and in vivo pharmacokinetic study in rat using an Immuno-affinity capture liquid chromatography-mass spectrometric method","volume":"11","author":"Park","year":"2021","journal-title":"Appl. Sci."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153145_bb0220","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/nprot.2010.111","article-title":"Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies","volume":"5","author":"de Graaf","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104920","article-title":"Host microbiota dictates the proinflammatory impact of LPS in the murine liver","volume":"67","author":"Suriguga","year":"2020","journal-title":"Toxicol. in Vitro"},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153145_bb0230","doi-asserted-by":"crossref","DOI":"10.1242\/bio.058678","article-title":"Specificity and off-target effects of AAV8-TBG viral vectors for the manipulation of hepatocellular gene expression in mice","volume":"10","author":"Kiourtis","year":"2021","journal-title":"Biol. Open"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153145_bb0235","doi-asserted-by":"crossref","first-page":"4230","DOI":"10.1016\/S0021-9258(18)34710-0","article-title":"Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line","volume":"257","author":"Schwartz","year":"1982","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0240","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/156800912798888983","article-title":"Targeting urokinase and the transferrin receptor with novel, anti-mitotic N-alkylisatin cytotoxin conjugates causes selective cancer cell death and reduces tumor growth","volume":"12","author":"Vine","year":"2012","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ijbiomac.2026.153145_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2023.100172","article-title":"Development of novel liver-targeting glucocorticoid prodrugs","volume":"21","author":"Wang","year":"2024","journal-title":"medicine in Drug Discovery"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153145_bb0250","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153145_bb0255","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1039\/C7OB02780J","article-title":"Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates","volume":"16","author":"Bryden","year":"2018","journal-title":"Org. Biomol. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153145_bb0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4161\/mabs.3.2.14960","article-title":"Analytical methods for physicochemical characterization of antibody drug conjugates","volume":"3","author":"Wakankar","year":"2011","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0265","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s10020-024-00992-8","article-title":"TAT as a new marker and its use for noninvasive chemical biopsy in NASH diagnosis","volume":"30","author":"Jo","year":"2024","journal-title":"Mol. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153145_bb0270","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1080\/19420862.2017.1373924","article-title":"Capacity limits of asialoglycoprotein receptor-mediated liver targeting","volume":"9","author":"Bon","year":"2017","journal-title":"MAbs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153145_bb0275","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/abt\/tbae005","article-title":"Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate","volume":"7","author":"Ma","year":"2024","journal-title":"Antibody Therapeutics"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153145_bb0280","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.ymthe.2022.04.013","article-title":"A highly stable human single-domain antibody-drug conjugate exhibits superior penetration and treatment of solid tumors","volume":"30","author":"Wu","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0285","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.153145_bb0290","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153145_bb0295","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.ijbiomac.2026.153145_bb0300","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/0024-3205(95)02176-J","article-title":"Precision-cut tissue slices: applications in pharmacology and toxicology","volume":"57","author":"Parrish","year":"1995","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0887-2333(97)00097-0","article-title":"Liver slices in in vitro pharmacotoxicology with special reference to the use of human liver tissue","volume":"12","author":"Olinga","year":"1997","journal-title":"Toxicol. in Vitro"},{"issue":"24","key":"10.1016\/j.ijbiomac.2026.153145_bb0310","doi-asserted-by":"crossref","first-page":"8697","DOI":"10.1158\/1078-0432.CCR-04-1166","article-title":"A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity","volume":"10","author":"Kirby","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153145_bb0315","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/17425255.3.6.879","article-title":"Precision-cut tissue slices as a tool to predict metabolism of novel drugs","volume":"3","author":"Graaf","year":"2007","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153145_bb0320","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/00498254.2012.723151","article-title":"Evaluation of fibrosis in precision-cut tissue slices","volume":"43","author":"Westra","year":"2013","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153145_bb0325","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.tiv.2007.11.019","article-title":"Liver slices as a model to study fibrogenesis and test the effects of anti-fibrotic drugs on fibrogenic cells in human liver","volume":"22","author":"van de Bovenkamp","year":"2008","journal-title":"Toxicol. in Vitro"},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.153145_bb0330","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1111\/bph.13945","article-title":"Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis","volume":"174","author":"Luangmonkong","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153145_bb0335","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/nprot.2016.097","article-title":"Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation","volume":"11","author":"Broutier","year":"2016","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153145_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.11.013","article-title":"Long-term expansion of functional mouse and human hepatocytes as 3D organoids","volume":"175","author":"Hu","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153145_bb0345","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/hep.32620","article-title":"Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness","volume":"77","author":"Indira Chandran","year":"2022","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153145_bb0350","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.gastha.2023.03.006","article-title":"Obese patients with nonalcoholic fatty liver disease have an increase in soluble plasma CD163 and a concurrent decrease in hepatic expression of CD163","volume":"2","author":"Skytthe","year":"2023","journal-title":"Gastro Hep Adv"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026030722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:29:07Z","timestamp":1790468947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026030722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":70,"alternative-id":["S0141813026030722"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153145","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and preclinical evaluation of an asialoglycoprotein receptor 1-targeted antibody-drug conjugate in hepatic inflammation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"153145"}}